Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy

Register of interests (PDF 288 KB)

Equality Impact Assessment (Guidance development) (PDF 146 KB)

Final evaluation determination

Committee papers (PDF 7.54 MB)

Public committee slides (PDF 928 KB)

Final evaluation determination document Equality Impact Assessment (PDF 146 KB)

Final evaluation determination document (PDF 240 KB)

Final scope (PDF 172 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 442 KB)

Equality impact assessment (Scoping) (PDF 126 KB)

Final stakeholder list (PDF 210 KB)

Draft scope post referral (PDF 189 KB)

Draft matrix post referral (PDF 209 KB)